APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
Public ClinicalTrials.gov record NCT03997383. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
Study identification
- NCT ID
- NCT03997383
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Enrollment
- 360 participants
Conditions and interventions
Interventions
- Patisiran Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 3, 2019
- Primary completion
- Jun 19, 2022
- Completion
- Dec 23, 2025
- Last update posted
- Apr 19, 2026
2019 – 2025
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Trial Site | Los Angeles | California | 90048 | — |
| Clinical Trial Site | Chicago | Illinois | 60637 | — |
| Clinical Trial Site | Skokie | Illinois | 60076 | — |
| Clinical Trial Site | Iowa City | Iowa | 52242 | — |
| Clinical Trial Site | Kansas City | Kansas | 66160 | — |
| Clinical Trial Site | Baltimore | Maryland | 21224 | — |
| Clinical Trial Site | Boston | Massachusetts | 02118 | — |
| Clinical Trial Site | Burlington | Massachusetts | 10805 | — |
| Clinical Trial Site | Rochester | Minnesota | 55905 | — |
| Clinical Trial Site | St Louis | Missouri | 63110 | — |
| Clinical Trial Site | New York | New York | 10029 | — |
| Clinical Trial Site | New York | New York | 10032 | — |
| Clinical Trial Site | Cleveland | Ohio | 44195 | — |
| Clinical Trial Site | Philadelphia | Pennsylvania | 19104 | — |
| Clinical Trial Site | Philadelphia | Pennsylvania | 19140 | — |
| Clinical Trial Site | Pittsburgh | Pennsylvania | 15212 | — |
| Clinical Trial Site | Nashville | Tennessee | 37232 | — |
| Clinical Trial Site | Dallas | Texas | 75246 | — |
| Clinical Trial Site | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 71 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03997383, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 19, 2026 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03997383 live on ClinicalTrials.gov.